All In Biotech

Drug Trial Radar · NCT01252810

Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure

Last checked: Nov 19, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Nov 2010

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
i3 Statprobe; Medpace, Inc.; Biomedical Systems; Rules-Based Medicine, Inc.
First posted
Dec 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class III or greater, who are referred for a coronary catheterization procedure with or without PCI.

Conditions

  • Chronic Renal Insufficiency
  • Diabete Mellitus
  • Congestive Heart Failure

Interventions

  • GE-145Drug

    GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.Time frame: After the imaging date for either Ioforminol or Iopamidol.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GE Healthcare

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.